welldesign
prospect
analysi
incid
ard
unit
state
carri
populationbas
cohort
studi
hospit
king
counti
washington
april
juli
focus
primarili
investig
use
valid
screen
protocol
identifi
patient
ard
defin
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
ratio
mmhg
bilater
chest
radiograph
opac
without
evid
leftsid
heart
failur
basi
data
author
estim
annual
incid
case
ard
unit
state
hospit
mortal
subsequ
lungsaf
studi
provid
valuabl
data
crosssect
analysi
patient
countri
winter
studi
preval
ard
patient
intens
care
ard
identifi
ventil
patient
detail
review
ard
incid
timerel
chang
epidemiolog
factor
recent
lungsaf
studi
also
report
hospit
mortal
patient
mild
ard
moder
ard
sever
ard
berlin
box
howev
remain
unclear
much
report
mortal
ard
attribut
ard
oppos
underli
comorbid
cancer
immunosuppress
associ
nonpulmonari
organ
dysfunct
cardiovascular
insuffici
septic
shock
liver
dysfunct
renal
failur
andor
older
age
patient
condit
exampl
followup
analysi
lungsaf
studi
determin
patient
ard
studi
immunocompromis
hospit
mortal
much
higher
patient
nonimmunocompromis
patient
versu
p
importantli
lungsaf
studi
reveal
clinician
recognit
ard
low
mild
ard
sever
ard
furthermor
fewer
twothird
patient
ard
treat
optim
tidal
volum
mechan
ventil
ml
per
kg
predict
bodi
weight
pbw
thu
studi
confirm
ard
remain
common
critic
ill
patient
underrecogn
undertr
sever
comorbid
exposur
associ
increas
suscept
ard
includ
alcohol
cigarett
air
diabet
mellitu
associ
lower
risk
ard
develop
reason
remain
although
data
lungsaf
studi
show
associ
diabet
diagnosi
ard
develop
ard
outcom
twocentr
clinic
studi
identifi
major
recipi
risk
factor
develop
trali
includ
recent
liver
surgeri
chronic
alcohol
abus
current
cigarett
smoke
higher
peak
airway
pressur
highest
airway
pressur
ventil
posit
fluid
transfus
risk
factor
receipt
whole
blood
fresh
frozen
plasma
femal
donor
quantiti
human
leukocyt
antigen
hla
class
ii
antibodi
volum
concentr
antihuman
neutrophil
antigen
transfus
blood
compon
risk
associ
age
store
blood
inde
elimin
fresh
frozen
plasma
wholeblood
transfus
femal
donor
markedli
reduc
incid
trali
implic
role
allogen
antibodi
pathogenesi
trali
blunt
penetr
trauma
sever
durat
shock
chest
injuri
number
blood
product
transfus
presenc
traumat
brain
injuri
quantiti
crystalloid
fluid
volum
expand
contribut
risk
develop
studi
associ
ethnic
ard
outcom
larg
uniformli
report
higher
mortal
black
hispan
patient
ard
white
analysi
patient
die
diagnost
code
ard
unit
state
men
higher
averag
ardsrel
mortal
women
black
patient
higher
mortal
white
patient
echo
find
similar
analys
prior
aetiolog
dispar
remain
unknown
studi
design
identifi
genet
factor
might
contribut
suscept
develop
ard
report
past
decad
howev
specif
loci
genomewid
signific
associ
ard
identifi
probabl
part
phenotyp
complex
ard
engend
differ
risk
howev
strategi
includ
candid
gene
pathway
analys
reveal
potenti
import
mechan
lung
injuri
seem
associ
risk
develop
ard
associ
higher
exampl
plasma
angiopoietin
encod
protein
marker
mediat
increas
lung
vascular
permeabl
use
quantit
trait
loci
analysi
five
genet
variant
popul
european
ancestri
associ
increas
level
plasma
angiopoietin
two
five
variant
associ
increas
ard
risk
signific
associ
found
gene
peopl
african
systemat
review
paediatr
pardi
crosssect
studi
intern
paediatr
intens
care
unit
picu
estim
populationbas
incid
ard
children
week
year
age
per
personyear
children
studi
year
age
ard
diagnos
picu
admiss
estim
mortal
mortal
lower
highli
resourc
countri
associ
age
past
two
decad
ard
mortal
picu
rel
stabl
although
overal
number
ardsassoci
death
lower
children
adult
product
life
year
lost
ardsrel
paediatr
death
occur
young
patient
patient
previous
major
risk
factor
pathophysiolog
ard
similar
adult
paediatr
adult
ard
epidemiolog
differ
ard
frequent
boy
reason
unknown
paediatr
ard
pard
also
caus
pneumonia
howev
viral
infect
respiratori
syncyti
viru
influenza
viru
frequent
caus
lifethreaten
ard
young
overal
mortal
lowest
children
ard
trigger
lower
respiratori
infect
highest
indirect
lung
injuri
sepsi
andor
ard
occur
paediatr
trauma
patient
associ
mortal
incid
present
outcom
trali
children
seem
similar
adult
histori
prematur
cancer
immun
compromis
risk
factor
mortal
sever
hypoxaemia
consist
predict
mortal
paediatr
intub
children
pardi
studi
sever
ard
defin
mmhg
associ
threefold
higher
mortal
children
mmhg
addit
histori
cancer
haematopoiet
stem
cell
transplant
paediatr
patient
ard
result
mortal
versu
children
without
risk
factor
prospect
multicentr
interstiti
alveolar
oedema
key
featur
diffus
alveolar
damag
dad
acut
exud
phase
day
ard
fig
eosinophil
deposit
term
hyalin
membran
also
defin
featur
dad
classic
histopatholog
hallmark
find
includ
alveolar
haemorrhag
accumul
white
blood
cell
usual
predominantli
neutrophil
fibrin
deposit
area
alveolar
atelectasi
collaps
initi
exud
phase
atii
cell
hyperplasia
follow
prolif
phase
last
week
survivor
interstiti
fibrosi
also
occur
phase
origin
descript
dad
base
heavili
analys
lung
patient
die
oxygen
toxic
although
similar
histolog
chang
identifi
lung
patient
varieti
condit
underli
recent
report
reveal
dad
present
subset
patient
clinic
ard
patholog
heterogen
exampl
one
studi
carri
two
decad
postmortem
sampl
report
patient
met
berlin
criteria
ard
dad
wherea
alveolar
inflamm
consist
acut
pneumonia
infiltr
neutrophil
alveoli
distal
importantli
studi
also
found
incid
dad
declin
decad
lungprotect
ventil
implement
recent
report
also
indic
key
tempor
featur
histolog
progress
identifi
associ
dad
sever
ard
provid
evid
first
day
onset
repres
critic
window
potenti
therapeut
addit
one
metaanalysi
open
lung
biopsi
sampl
patient
ard
found
dad
present
patient
associ
higher
neither
sever
hypoxaemia
sequenti
organ
failur
assess
score
differ
patient
without
dad
lung
biopsi
classic
electron
microscop
analys
demonstr
alter
endotheli
epitheli
cell
critic
featur
acut
alveolar
injuri
exampl
earli
involv
ati
cell
frequent
dramat
includ
focal
epitheli
destruct
denud
alveolar
basement
contrast
alveolar
endotheli
cell
usual
morpholog
preserv
endotheli
line
continu
demonstr
even
ultrastructur
analys
precis
detect
abnorm
normal
barrier
properti
regul
fluid
protein
flux
across
lung
epitheli
cell
necrosi
usual
describ
exud
although
evid
apoptosi
also
earli
epitheli
injuri
follow
rapidli
atii
cell
injur
intact
alveolar
epitheli
cell
seem
drive
releas
procoagul
factor
intraalveolar
fibrin
also
deposit
adjac
endotheli
cell
injur
studi
use
cultur
endothelium
murin
model
indic
homophil
calciumdepend
vascular
endotheli
cadherin
vecadherin
bond
adjac
endotheli
cell
critic
basal
lung
microvascular
integr
loosen
central
increas
permeabl
inflammatori
acut
lung
vecadherin
endotheli
receptor
kinas
act
concert
establish
junction
integr
regul
vascular
endothelialprotein
tyrosin
phosphatas
veptp
also
known
receptortyp
tyrosineprotein
phosphatas
genet
pharmacolog
manipul
molecular
interact
activ
vecadherin
veptp
alter
alveolar
leak
complex
fashion
vecadherin
function
adheren
junction
stabil
also
regul
cytoskelet
interact
small
gtpase
intracellular
modul
multipl
molecular
interact
includ
associ
catenin
plakoglobin
veptp
phosphoryl
dephosphoryl
destabil
signal
pathogen
inflammatori
cell
mediat
respond
infecti
agent
induc
phosphoryl
vecadherin
intern
frequent
alter
activ
balanc
dissoci
veptp
vecadherin
requir
loosen
endotheli
cell
junction
inflammatori
alveolar
protein
leak
recent
observ
indic
inflammationinduc
weaken
endotheli
junction
process
involv
least
two
step
includ
modif
vecadherin
contact
alter
endotheli
actomyosin
genet
pharmacolog
manipul
veptp
alter
alveolar
endotheli
junction
via
influenc
cytoskeleton
independ
although
parallel
experi
cultur
human
endotheli
cell
suggest
translat
direct
recapitul
observ
alveolar
endotheli
barrier
disrupt
patient
ard
establish
nevertheless
administr
mice
antibodi
vecadherin
result
intravascular
sequestr
neutrophil
platelet
alveolar
neutrophil
accumul
pulmonari
mimick
histolog
pattern
clinic
note
substanti
alveolar
oedema
experiment
acut
lung
injuri
accompani
widespread
overt
disrupt
endotheli
cell
junction
detect
electron
consist
ultrastructur
observ
lung
tissu
patient
ard
endothelium
found
larg
continu
endotheli
cell
junction
part
morpholog
thu
anim
model
human
ard
chang
paracellular
permeabl
protein
seem
occur
absenc
dramat
alter
morpholog
lung
endothelium
reestablish
endotheli
junction
bond
may
mitig
endotheli
leak
excess
myeloid
leukocyt
accumul
inde
genet
replac
vecadherin
fusion
construct
prevent
intern
respons
inflammatori
signal
greatli
reduc
alveolar
neutrophil
accumul
lipopolysaccharidechalleng
mice
reduc
vascular
recent
analysi
sampl
patient
lipopolysaccharidechalleng
volunt
indic
synergist
activ
chemokin
contribut
neutrophil
signal
molecul
also
like
degranul
neutrophil
releas
intracellular
enzym
neutrophil
elastas
oxid
product
contribut
lung
neutrophil
intravascular
extravascular
compart
acut
lung
injuri
often
associ
platelet
fig
intric
thromboinflammatori
activ
includ
abil
trigger
deploy
neutrophil
extracellular
trap
net
net
correl
epitheli
barrier
disrupt
ard
experiment
net
filament
chromatin
fibr
complex
neutrophilderiv
antimicrobi
protein
gener
process
complet
defin
net
probabl
evolv
innat
mechan
pathogen
contain
clearanc
also
involv
inflammatori
insult
lung
organ
illustr
recent
experiment
clinic
studi
acut
lung
injuri
recent
observ
suggest
earli
intravascular
interact
platelet
monocyt
similar
neutrophil
accumul
complex
activ
acut
lung
injuri
drive
develop
ard
individu
intraalveolar
macrophag
play
import
part
releas
chemotact
factor
chemokin
ccchemokin
ligand
also
known
enhanc
recruit
neutrophil
monocyt
lung
particularli
respons
acut
pulmonari
infect
earli
phase
experiment
acut
lung
injuri
epithelium
resist
injuri
describ
degre
epitheli
injuri
characterist
ard
extent
epitheli
injuri
also
import
determin
sever
ard
epithelium
injur
directli
exampl
bacteri
product
virus
acid
oxygen
toxic
hyperoxia
hypoxia
mechan
forc
inflammatori
cell
product
sepsi
trali
pancreat
fig
endotheli
epitheli
injuri
includ
dissoci
intercellular
releas
cellfre
haemoglobin
red
blood
cell
contribut
paracellular
permeabl
oxidantdepend
mechan
basi
experiment
studi
cyclooxygenas
inhibitor
acetaminophen
reduc
tyrosin
radic
result
oxid
cellfre
haemoglobin
oxid
state
oxid
state
therebi
reduc
potenti
lipid
addit
epitheli
cell
apoptot
key
featur
alveolar
injuri
ard
directli
caus
lytic
viral
infect
bacteri
toxin
acid
hypoxia
hyperoxia
mechan
neutrophilderiv
mediat
also
induc
epitheli
cell
death
via
multipl
mechan
includ
oxid
solubl
tnf
ligand
superfamili
member
fasl
wherea
inflammatori
macrophag
induc
cell
death
via
mechan
includ
secret
tnfrelat
apoptosisinduc
ligand
trail
notabl
endogen
mechan
signal
limit
cell
addit
plasma
membran
wound
without
cell
death
subleth
injuri
may
result
bacteri
poreform
toxin
andor
overdistent
positivepressur
ventil
high
tidal
volum
recent
studi
demonstr
membran
wound
staphylococcu
aureu
toxin
calcium
wave
spread
gap
junction
neighbour
epitheli
cell
induc
widespread
mitochondri
dysfunct
loss
barrier
integr
without
cell
inde
mitochondri
dysfunct
common
lung
injuri
may
induc
variou
mechan
includ
repair
injur
epithelium
critic
clinic
time
frame
epitheli
repair
may
day
sever
week
ati
cell
provid
normal
surfac
area
alveolar
epithelium
facilit
ga
exchang
process
gener
new
ati
cell
critic
complet
repair
process
howev
initi
prolifer
atii
cell
provid
provision
epitheli
barrier
transdifferenti
ati
cell
fig
mani
growth
factor
contribut
atii
cell
prolifer
although
atii
cell
default
progenitor
respons
creat
new
alveolar
epitheli
cell
prolifer
sever
injuri
altern
progenitor
cell
may
mobil
altern
progenitor
cell
includ
club
secretori
cell
normal
line
airway
bronchoalveolar
stem
cell
expans
epitheli
progenitor
driven
fibrocyt
growth
factor
receptor
atii
cell
fate
induc
imped
notch
fig
mechan
underli
atiitoati
transdifferenti
less
well
understood
recent
studi
suggest
deactiv
knowledg
regen
role
altern
progenitor
mainli
base
mous
model
lung
injuri
although
evid
progenitor
exist
human
repair
alveolar
epithelium
regul
crosstalk
multipl
alveolar
cell
type
extracellular
matrix
although
injuryinduc
immun
cell
mediat
may
also
promot
epitheli
fibroblast
secret
epitheli
growth
factor
deposit
collagen
excess
lead
fibrosi
subleth
epitheli
cell
injuri
also
repair
exampl
plasma
membran
pore
excis
endocytosi
exocytosi
patch
fusion
lipid
endomembran
addit
damag
mitochondria
degrad
via
mitophagi
replac
via
biogenesi
mitochondri
final
reassembl
intercellular
junction
regul
multipl
mechan
includ
benefici
effect
angiopoietin
signal
basement
time
endotheli
epitheli
repair
variou
caus
acut
lung
injuri
systemat
work
epitheli
barrier
integr
restor
oedemat
fluid
reabsorb
interstitium
either
paracellular
pathway
diffus
water
channel
driven
osmot
gradient
establish
activ
apic
sodium
uptak
part
epitheli
sodium
channel
sodium
transport
nakatpas
pump
fig
unfortun
mani
endogen
repar
mechan
specif
inhibit
ard
exampl
influenza
viru
infect
influenza
infect
hypoxaemia
hypercapnia
factor
downregul
sodium
channel
andor
nakatpas
function
result
impair
alveolar
fluid
clearanc
patient
hypercapnia
impair
alveolar
epitheli
cell
keratinocyt
growth
factor
stimul
prolifer
increas
suscept
atii
cell
influenza
viru
infect
mortal
addit
mani
biolog
chang
result
endotheli
epitheli
injuri
culmin
proteinrich
oedemat
fluid
contribut
surfact
surfact
dysfunct
increas
atelectasi
turn
increas
risk
biophys
injuri
mechan
injur
lung
endothelium
epithelium
lead
pulmonari
oedema
acut
respiratori
failur
owe
reduc
oxygen
impair
carbon
dioxid
excret
decreas
lung
complianc
describ
origin
report
ard
use
mechan
ventil
supplement
oxygen
posit
endexpiratori
pressur
peep
lifesav
context
mani
year
standard
therapi
mechan
ventil
support
includ
high
tidal
volum
ml
per
kg
pbw
nevertheless
potenti
contribut
high
tidal
volum
elev
airway
pressur
worsen
acut
lung
injuri
suggest
preclin
studi
begin
clinic
import
vali
provid
arma
trial
see
manag
lower
tidal
volum
limit
airway
pressur
markedli
reduc
mortal
patient
mechan
vali
establish
experiment
clinic
studi
high
tidal
volum
elev
airway
pressur
induc
biomechan
inflammatori
injuri
necrosi
lung
endothelium
alveolar
epithelium
associ
releas
neutrophil
product
includ
proteas
oxid
proinflammatori
cytokin
reduct
capac
alveolar
epithelium
remov
oedemat
clinic
studi
focus
biolog
clinic
factor
also
confirm
injuri
effect
high
tidal
volum
patient
ard
see
emphas
possibl
elimin
vali
still
occur
dyssynchroni
elev
plateau
airway
pressur
elev
pressur
gener
mechan
ventil
alveoli
especi
patient
sever
lung
injuri
extens
pulmonari
oedema
except
support
care
therapi
lungprotect
ventil
fluidconserv
therapi
see
manag
translat
insight
experiment
studi
anim
model
effect
therapi
human
ard
prove
challeng
inde
search
specif
pharmacotherapi
effect
treat
ard
fruitless
despit
decad
promis
preclin
attempt
overcom
obstacl
investig
sought
understand
biolog
human
ard
studi
human
sampl
obtain
observ
intervent
clinic
studi
studi
patient
ard
valid
sever
pathophysiolog
observ
experiment
studi
led
identif
promis
prognost
biomark
human
box
identifi
molecular
subphenotyp
human
ard
may
therapeut
implic
initi
studi
ard
pathogenesi
use
human
sampl
confirm
biolog
mechan
identifi
mani
model
relev
import
initi
observ
includ
confirm
human
fundament
hallmark
ard
disrupt
barrier
document
elev
protein
level
pulmonari
oedemat
subsequ
studi
biolog
marker
bronchoalveolar
lavag
pulmonari
oedemat
fluid
commonli
plasma
readili
avail
case
demonstr
endotheli
exagger
inflammatori
consist
featur
human
ard
endotheli
activ
particular
seem
occur
earli
develop
human
ard
case
predat
frank
respiratori
lung
epitheli
injuri
human
ard
identifi
measur
impair
alveolar
fluid
recent
measur
specif
marker
alveolar
epitheli
cell
injuri
includ
surfact
protein
receptor
advanc
glycat
end
product
rage
marker
lung
epitheli
injuri
innat
immun
importantli
mani
marker
injuri
also
link
poor
clinic
outcom
ard
box
suggest
sever
endotheli
epitheli
injuri
human
major
determin
clinic
biolog
sampl
intervent
clinic
trial
ard
prove
particularli
use
further
understand
ard
pathogenesi
one
exampl
analysi
plasma
inflammatori
marker
patient
enrol
semin
trial
low
tidal
volum
ventil
demonstr
lungprotect
ventil
strategi
decreas
circul
marker
inflamm
compar
tradit
high
tidal
volum
analys
plasma
level
rage
trial
confirm
lungprotect
ventil
also
decreas
alveolar
epitheli
cell
injuri
compar
tradit
tidal
anoth
studi
report
reduct
distal
airspac
tnf
neutrophil
patient
treat
lungprotect
ventil
recent
analys
biolog
sampl
larg
clinic
trial
enabl
studi
focus
heterogen
ard
specif
identif
molecular
subphenotyp
ard
may
respond
differ
therapi
mani
medic
disciplin
notabl
oncolog
identif
discret
molecular
subtyp
within
broader
clinic
syndrom
led
remark
therapeut
progress
revis
diagnost
paradigm
consid
instanc
hormon
receptor
statu
breast
cancer
ard
biolog
heterogen
long
suspect
potenti
obstacl
success
develop
therapeut
earli
descript
syndrom
specul
whether
direct
pulmonari
indirect
nonpulmonari
caus
ard
exampl
might
patholog
support
hypothesi
recent
analysi
direct
indirect
ard
two
clinic
cohort
show
patient
direct
lung
injuri
higher
plasma
level
biomark
lung
epitheli
injuri
rage
surfact
protein
wherea
patient
indirect
lung
injuri
higher
plasma
level
biomark
endotheli
injuri
inflamm
includ
angiopoietin
altern
approach
deconvolut
ard
heterogen
use
unsupervis
analyt
approach
promin
latent
class
analysi
identifi
subphenotyp
within
ard
approach
replic
analys
five
clinic
trial
find
strong
evid
two
distinct
subphenotyp
approxim
patient
ard
consist
fall
socal
hyperinflammatori
subphenotyp
character
high
plasma
level
inflammatori
biomark
solubl
tnf
receptor
low
protein
c
high
preval
shock
metabol
acidosi
contrast
socal
hypoinflammatori
subphenotyp
compris
patient
lower
level
inflammatori
biomark
less
acidosi
less
vasopressordepend
shock
mortal
higher
hyperinflammatori
subphenotyp
hypoinflammatori
subphenotyp
five
clinic
trial
secondari
analys
complet
random
control
trial
two
ard
subphenotyp
respond
differ
peep
fluid
manag
interest
simvastatin
statin
propos
treatment
ard
potenti
antiinflammatori
properti
random
placebocontrol
clinic
trial
simvastatin
patient
ard
effect
howev
secondari
analysi
trial
data
reveal
patient
classifi
hyperinflammatori
subphenotyp
treat
simvastatin
significantli
higher
surviv
hyperinflammatori
patient
treat
placebo
differ
surviv
hypoinflammatori
patient
treat
simvastatin
valid
prospect
clinic
studi
approach
suggest
futur
clinic
trial
target
patient
basi
distinct
biolog
subphenotyp
may
success
trial
base
clinic
syndrom
definit
definit
mechanist
differ
two
subphenotyp
includ
whether
driven
environment
genet
factor
remain
yet
identifi
goal
integr
biolog
clinic
variabl
greatest
valu
predict
prognost
enrich
clinic
trial
requir
research
addit
research
studi
transcriptom
observ
clinic
trial
ard
need
identifi
pattern
may
help
segreg
pathway
lung
system
injuri
one
recent
studi
observ
cohort
patient
sepsisrel
ard
use
microarray
analysi
compar
wholeblood
gene
express
patient
stratifi
reactiv
cohort
uninflam
subphenotyp
reactiv
subphenotyp
gene
associ
neutrophil
express
uninflam
subphenotyp
pathway
analysi
reactiv
patient
group
show
enrich
oxid
phosphoryl
mitochondri
dysfunct
cholesterol
metabol
wherea
uninflam
group
show
pattern
associ
cell
prolifer
futur
studi
includ
rnasequenc
reduc
bia
compar
microarray
approach
studi
includ
sampl
blood
distal
airspac
provid
insight
pulmonari
versu
system
pathway
contribut
lung
studi
link
gene
express
protein
express
help
illustr
one
prior
studi
sepsisrel
even
develop
refin
berlin
diagnost
criteria
box
sever
aspect
diagnos
ard
remain
challeng
chest
radiograph
interpret
inher
present
subject
investig
studi
chest
radiograph
interpret
ard
particular
demonstr
suboptim
interrat
similarli
differenti
ard
hydrostat
pulmonari
oedema
due
heart
failur
andor
volum
overload
difficult
critic
ill
patient
fig
consensu
definit
ard
includ
requir
pulmonari
arteri
wedg
pressur
mmhg
measur
howev
pulmonari
arteri
cathet
rare
use
set
primarili
random
trial
show
clinic
benefit
use
compar
central
venou
cathet
patient
berlin
definit
ard
recommend
use
echocardiographi
assess
cardiac
function
clear
ard
risk
factor
identifi
test
may
use
distinct
includ
measur
brain
natriuret
peptid
bnp
elev
suggest
cardiac
insuffici
assess
vascular
pedicl
width
chest
radiograph
suggest
intravascular
volum
overload
andor
measur
ratio
protein
pulmonari
oedema
fluid
plasma
suggest
elev
lung
vascular
pressur
cardiogen
pulmonari
oedema
versu
ratio
suggest
increas
permeabl
ard
although
test
less
wide
complex
may
contribut
persist
underrecognit
ard
clinician
underresourc
set
without
readi
access
advanc
diagnost
modal
therapi
diagnosi
ard
hinder
thu
investig
propos
altern
criteria
ard
diagnosi
absenc
chest
radiographi
mechan
ventil
andor
blood
ga
measur
socal
kigali
modif
berlin
box
anoth
import
aspect
diagnos
ard
depend
exclud
mimic
syndrom
may
requir
specif
treatment
mimic
includ
acut
eosinophil
pneumonia
diffus
alveolar
haemorrhag
acut
interstiti
pneumonia
cryptogen
organ
pneumonia
acut
exacerb
idiopath
pulmonari
fibrosi
acut
heart
failur
fig
ard
occur
set
underli
risk
factor
exampl
sepsi
pneumonia
sever
trauma
identif
risk
factor
requir
ensur
patient
actual
ard
ard
mimic
treatment
underli
risk
factor
vital
import
patient
care
ard
risk
factor
readili
appar
suspicion
ard
mimic
increas
case
bronchoscopi
bronchoalveolar
lavag
cell
count
differenti
help
diagnost
aetiolog
remain
unclear
bronchoscopi
lung
biopsi
thoracoscop
less
commonli
open
may
consid
result
would
chang
patient
manag
studi
diagnost
yield
lung
biopsi
sampl
set
report
vari
diagnost
yield
substanti
morbid
mortal
recent
review
provid
thought
algorithm
consid
lung
biopsi
given
differ
ard
adult
children
intern
pediatr
acut
lung
injuri
consensu
confer
palicc
defin
criteria
box
major
differ
palicc
pard
definit
adult
consensu
confer
berlin
definit
pard
kigali
modif
berlin
definit
peripher
capillari
oxygen
satur
ratio
use
arteri
avail
howev
lung
ultrasonographi
incorpor
diagnost
criteria
presenc
bilater
radiograph
opac
use
distinguish
diffus
lung
diseas
difficult
detect
accuraci
requir
hypoxia
assess
intub
children
requir
adjust
level
respiratori
support
use
mean
airway
pressur
map
calcul
oxygen
box
neonat
outsid
perinat
period
includ
pard
definit
addit
criteria
diagnos
pard
children
paediatr
cyanot
congenit
heart
diseas
chronic
lung
diseas
pard
definit
inclus
aim
diagnos
ard
earli
stage
children
diagnos
pard
use
palicc
criteria
mortal
also
met
berlin
criteria
versu
patient
treat
noninvas
ventil
use
oxygen
satur
ratio
diagnosi
unilater
infiltr
mortal
neonat
lung
diseas
expert
propos
consensu
definit
neonat
ard
call
montreaux
propos
neonat
birth
week
postmenstru
age
week
born
term
children
respiratori
distress
syndrom
prematur
surfact
defici
transient
tachypnoea
newborn
congenit
anomali
caus
respiratori
condit
exclud
montreaux
definit
similar
palicc
pard
definit
box
term
time
use
palicc
cutoff
oxygen
index
requir
arteri
transcutan
oxygen
tension
valu
rather
furthermor
determin
origin
oedema
requir
use
echocardiographi
verifi
absenc
congenit
heart
diseas
contributor
imag
must
show
diffus
bilater
infiltr
complet
lung
opacif
valid
definit
need
larg
prospect
cohort
autopsi
pathophysiolog
correl
differenti
ard
caus
hypoxaemia
comprehens
histori
physic
examin
radiograph
imag
includ
chest
radiograph
sometim
abdomin
imag
laboratori
test
requir
search
clinic
risk
factor
associ
ard
bacteri
viral
respiratori
infect
lung
includ
secondari
bacteri
infect
initi
viral
infect
common
risk
factor
associ
ard
section
focus
pulmonari
infect
part
diagnost
workup
typic
diagnost
approach
includ
blood
cultur
microscop
examin
cultur
respiratori
specimen
evalu
patient
suspect
ard
like
caus
pathogen
pathogen
sever
factor
taken
consider
whether
infect
communityacquir
healthcareassoci
import
determin
potenti
pathogen
fig
import
factor
includ
age
presenc
comorbid
condit
exposur
histori
vaccin
statu
addit
commonli
isol
organ
physician
consid
uncommon
import
pathogen
link
travel
resid
certain
geograph
distribut
specif
exposur
exampl
includ
middl
east
respiratori
syndrom
coronaviru
merscov
avian
influenza
virus
hantaviru
human
adenoviru
plasmodium
speci
blastomyc
dermatitidi
coxiella
burnetti
coccidioidomycosi
histoplasmosi
mycobacterium
tuberculosi
yersinia
pesti
fig
instanc
patient
travel
saudi
arabia
expos
camel
higher
risk
develop
merscov
patient
live
central
valley
california
higher
risk
develop
coccidioidomycosi
patient
without
identifi
pathogen
use
tradit
microbiolog
test
tracheal
aspir
sputum
examin
use
bronchoalveolar
lavag
lead
identif
pathogen
patient
percentag
patient
ard
identifi
organ
even
bronchoalveolar
lavag
examin
remain
high
pathogen
marker
dna
also
enter
bloodstream
may
futur
enabl
pathogen
identif
without
need
bronchoalveolar
nucleic
acid
detect
test
pcr
avail
detect
multipl
common
virus
bacteria
mycoplasma
spp
chlamydia
pneumonia
bordetella
pertussi
pcr
panel
identifi
quantifi
common
bacteria
aureu
streptococcu
pneumonia
also
becom
avail
howev
establish
causat
remain
challeng
test
differenti
pathogen
colon
distinguish
primari
pathogen
trigger
ard
pathogen
may
invad
secondarili
addit
variabl
avail
pcr
test
local
test
practic
specimen
time
qualiti
type
sputum
versu
bronchoalveolar
lavag
influenc
pathogen
identif
influenc
report
epidemiolog
nextgener
sequenc
like
becom
common
detect
pathogen
may
chang
understand
ard
increas
test
sensit
identifi
pathogen
frequent
colon
respiratori
tract
patient
pneumonia
howev
physician
need
consid
pretest
probabl
interpret
result
exampl
virus
respiratori
syncyti
viru
human
metapneumoviru
like
caus
ard
young
children
elderli
individu
immunosuppress
individu
final
alway
import
consid
nonpulmonari
caus
ard
includ
intraabdomin
infect
present
neither
strong
evid
consensu
regard
whether
patient
screen
ard
ard
occur
minor
patient
risk
factor
make
screen
furthermor
ard
develop
often
occur
quit
quickli
major
patient
go
develop
ard
first
hour
clinic
score
develop
predict
ard
atrisk
patient
promin
lung
injuri
predict
score
lip
lip
synthes
avail
clinic
data
includ
predispos
risk
factor
comorbid
acut
physiolog
variabl
gener
risk
score
higher
score
indic
greater
risk
develop
ard
neg
predict
valu
lip
high
posit
predict
valu
even
origin
descript
low
lip
clinic
trial
use
lip
cutoff
enrol
criterion
found
even
lower
posit
predict
valu
altern
approach
earli
acut
lung
injuri
eali
score
aim
identifi
patient
incipi
lung
injuri
frank
simpler
score
develop
analysi
patient
acut
bilater
radiograph
opac
compris
three
variabl
level
supplement
oxygen
requir
tachypnoea
presenc
immun
suppress
comparison
lip
neg
predict
valu
eali
score
high
posit
predict
valu
better
although
lip
eali
score
rigor
test
children
pardi
studi
show
mani
children
mild
diseas
progress
meet
berlin
criteria
within
day
diagnos
pard
biomark
also
evalu
potenti
ard
predict
instrument
exampl
level
von
willebrand
factor
marker
endotheli
injuri
predict
develop
ard
small
studi
patient
nonpulmonari
recent
larger
studi
patient
sever
angiopoietin
also
found
elev
critic
ill
patient
ard
analysi
angiopoietin
improv
posit
predict
valu
lip
solubl
form
rage
report
predict
ard
develop
children
undergo
cardiac
recent
critic
ill
patient
risk
although
report
found
solubl
rage
predict
data
provid
import
evid
endotheli
lung
epitheli
injuri
well
underway
patient
fulfil
ard
diagnost
criteria
howev
biomark
question
clinic
avail
use
restrict
research
set
decad
clinician
research
wonder
whether
prevent
therapi
implement
earli
progress
acut
lung
injuri
patient
meet
ard
diagnost
criteria
could
improv
clinic
outcom
unfortun
trial
focus
prevent
use
pharmacotherapi
met
disappoint
result
earliest
trial
test
approach
corticosteroid
evalu
ard
prevent
atrisk
patient
evid
recent
phase
iib
clinic
trial
test
aspirin
prevent
therapi
atrisk
patient
although
subsequ
reanalysi
data
rais
interest
smaller
phase
iia
trial
aerosol
budesonid
corticosteroid
formoterol
longact
may
improv
alveolar
fluid
clearanc
demonstr
improv
oxygen
decreas
rate
progress
ard
treatment
group
although
baselin
random
imbal
may
affect
contrast
result
pharmacotherapi
trial
studi
evalu
use
low
tidal
volum
ventil
mechan
ventil
patient
without
ard
provid
evid
recent
larg
clinic
trial
compar
low
intermedi
tidal
volum
patient
without
ard
sever
studi
note
reduct
nosocomi
ard
incid
thought
associ
improv
support
although
true
prevent
trial
challeng
conduct
rapid
develop
low
incid
ard
altern
approach
test
valu
earli
treatment
patient
incipi
acut
hypoxaem
respiratori
failur
mani
case
progress
ard
french
trial
illustr
potenti
valu
approach
compar
highflow
nasal
cannula
noninvas
ventil
facemask
oxygen
nonintub
patient
mmhg
major
patient
pneumonia
bilater
radiograph
opac
chest
radiographi
indic
like
earli
ard
highflow
nasal
cannula
affect
primari
outcom
endotrach
intub
lead
statist
significantli
lower
mortal
noninvas
ventil
p
facemask
oxygen
p
trial
may
serv
use
paradigm
futur
earli
treatment
trial
select
patient
popul
especi
emphas
opportun
identifi
patient
earli
phase
acut
lung
injuri
endotrach
intub
fig
note
potenti
benefit
highflow
nasal
cannula
may
generaliz
across
patient
intens
care
recent
random
control
studi
show
highflow
oxygen
therapi
significantli
decreas
mortal
compar
standard
oxygen
therapi
among
critic
ill
immunocompromis
patient
acut
respiratori
ard
lung
nonuniformli
aerat
nonaer
area
predominantli
gravitydepend
region
owe
superimpos
weight
inflammatori
pulmonari
oedemat
aerat
lung
volum
much
smaller
normal
phenomenon
term
babi
lung
identifi
illustr
first
ct
scan
concept
babi
lung
account
low
complianc
respiratori
system
identifi
area
lung
consolid
oedema
inflamm
associ
thu
lower
tidal
volum
need
ard
prevent
region
overdistens
describ
howev
scale
tidal
volum
pbw
target
estim
healthi
lung
size
although
aerat
babi
lung
volum
differ
substanti
patient
although
crucial
import
use
low
tidal
volum
univers
accept
best
method
scale
tidal
volum
patientspecif
surrog
stress
strain
still
warrant
investig
target
airway
drive
pressur
plateau
pressur
minu
peep
one
strategi
tailor
tidal
volum
patientspecif
mechan
garner
consider
univers
safe
threshold
yet
valid
prospect
trial
patient
mild
lung
injuri
lower
risk
biophys
injuri
benefit
confer
lower
tidal
volum
weigh
risk
aggress
sedat
use
paralyt
need
achiev
intend
tidal
volum
realtim
bedsid
imag
techniqu
electr
imped
tomographi
hold
potenti
identifi
overdistens
tidal
recruit
breath
could
use
monitor
protect
ventil
individu
ventil
strategi
peep
key
element
protect
routin
appli
patient
ard
facilit
adequ
oxygen
maintain
alveolar
recruit
ideal
peep
might
suffici
high
prevent
cyclic
open
collaps
distal
airspac
tidal
ventil
yet
low
enough
avoid
tidal
overdistens
unfortun
still
reliabl
method
assess
bedsid
risktobenefit
ratio
differ
peep
level
individu
patient
titrat
peep
offset
oesophag
pressur
surrog
pleural
pressur
show
promis
singlecentr
result
followup
multicentr
trial
indic
benefit
clinic
outcom
titrat
peep
oesophagealguid
strategi
compar
empir
high
peep
patient
moder
sever
multicentr
clinic
trial
date
definit
shown
one
peep
titrat
strategi
provid
superior
patientcentr
howev
accord
data
studi
assess
lung
recruit
ct
metaanalysi
trial
suggest
higher
level
peep
might
prefer
moder
sever
ard
patient
mild
recruit
term
use
identifi
distal
airspac
lung
may
collaps
oedemat
could
inflat
higher
level
peep
therefor
particip
ga
exchang
howev
recent
studi
report
wors
outcom
strategi
aggress
recruit
manoeuvr
open
collaps
lung
high
peep
patient
moder
sever
ard
receiv
ml
per
kg
pbw
tidal
maxim
benefit
limit
risk
overdistens
reduct
tidal
volum
may
necessari
use
high
peep
role
recruit
manoeuvr
manag
ard
uncertain
wherea
brief
recruit
manoeuvr
exampl
second
continu
airway
pressur
appli
may
transient
improv
oxygen
patient
impact
repeat
manoeuvr
higher
airway
pressur
longer
durat
clinic
outcom
remain
modifi
region
distribut
transpulmonari
pressur
prone
posit
decreas
region
heterogen
lung
aerat
lead
improv
ga
exchang
decreas
risk
mechan
lung
multicentr
proseva
prone
posit
improv
surviv
shorten
durat
mechan
ventil
compar
supin
posit
unlik
prior
trial
yield
mix
result
proseva
enrol
patient
moder
sever
ard
mmhg
box
use
prone
posit
earli
patient
cours
prescrib
prone
posit
least
hour
per
day
tailor
treatment
cours
patient
recoveri
use
concomit
low
tidal
volum
ventil
potenti
requisit
therapeut
long
session
prone
posit
recommend
patient
sever
spontan
breath
patient
acut
lung
injuri
possibl
elev
transpulmonari
pressur
may
exacerb
degre
lung
injuri
therebi
rais
question
whether
intub
ventil
lower
tidal
volum
reduc
transpulmonari
pressur
might
addit
owe
high
respiratori
drive
ventil
patient
ard
frequent
exhibit
strong
respiratori
effort
even
receiv
high
dose
sed
respiratori
effort
may
result
sever
dyssynchroni
increas
mechan
lung
injuri
owe
high
transpulmonari
pressur
andor
cyclic
paralysi
prevent
effect
thu
neuromuscular
blockad
may
decreas
mechan
lung
injuri
multicentr
trial
patient
sever
ard
infus
neuromuscularblock
drug
cisatracurium
hour
improv
adjust
surviv
ventilatorfre
day
compar
deep
sedat
without
result
expect
soon
followup
multicentr
trial
compar
cisatracurium
protocol
sedat
manag
accord
usual
patient
mild
ard
box
avoid
invas
mechan
ventil
altogeth
may
benefici
invas
positivepressur
ventil
relat
cointervent
carri
risk
sed
infus
predispos
delirium
decreas
mobil
predispos
neuromuscular
weak
risk
ventilatorassoci
pneumonia
among
noninvas
positivepressur
ventil
improv
use
often
patient
mild
ard
without
clear
benefit
devic
interfac
may
influenc
patient
toler
highflow
oxygen
exampl
l
per
min
via
largebor
nasal
cannula
safe
well
toler
effect
support
patient
mild
ard
part
provid
low
level
peep
modestli
increas
carbon
dioxid
mention
earlier
one
recent
studi
found
highflow
nasal
cannula
led
lower
mortal
noninvas
ventil
usual
addit
studi
ongo
optim
threshold
proceed
intub
drawback
delay
invas
support
patient
progress
toward
well
defin
date
back
sever
preclin
studi
indic
elev
lung
vascular
hydrostat
pressur
would
increas
quantiti
pulmonari
oedema
anim
model
random
clinic
trial
patient
ard
demonstr
adopt
fluidconserv
approach
vasopressordepend
shock
resolv
led
increas
ventilatorfre
day
improv
oxygen
trial
fluidconserv
arm
guid
detail
algorithm
requir
measur
central
venou
pulmonari
arteri
wedg
pressur
measur
everi
hour
determin
use
diuret
achiev
lower
vascular
fill
pressur
sinc
trial
simplifi
fluidconserv
approach
recommend
reduc
overal
fluid
balanc
ml
per
day
patient
ard
longer
shock
reduc
intraven
fluid
use
diuret
presenc
haemodynam
instabl
transpulmonari
thermodilut
estim
extravascular
lung
water
could
help
identifi
risk
exacerb
pulmonari
oedema
volum
challeng
potenti
help
inform
resuscit
caution
overli
conserv
fluid
manag
cite
small
studi
suggest
fluidconserv
strategi
might
associ
longterm
cognit
impair
howev
methodolog
issu
potenti
survivorship
bia
underpow
limit
definit
trial
also
demonstr
valu
use
pulmonari
arteri
cathet
compar
central
venou
fluid
cathet
guid
fluid
manag
mention
random
control
trial
assess
conserv
fluid
therapi
children
ard
one
observ
studi
indic
elev
cumul
fluid
balanc
day
pard
associ
higher
mortal
especi
patient
concomit
acut
kidney
venoven
extracorpor
membran
oxygen
ecmo
treatment
blood
circul
outsid
bodi
oxygen
gasperm
membran
ecmo
propos
rescu
therapi
patient
establish
sever
ard
trial
patient
typic
sever
ard
box
suffici
correct
ga
exchang
inconsist
lungprotect
observ
data
influenza
viru
epidem
suggest
ecmo
rescu
may
role
patient
refractori
hypoxaemia
due
isol
pulmonari
one
trial
patient
sever
ard
refractori
hypoxaemia
andor
hypercapnia
randomli
assign
particip
ecmo
continu
convent
treatment
trial
report
absolut
reduct
mortal
ecmo
ventil
set
target
low
tidal
volum
achiev
plateau
airway
pressur
less
compar
convent
strategi
ml
per
kg
pbw
tidal
volum
plateau
airway
pressur
howev
clinic
substanti
effect
surviv
achiev
statist
signific
p
leav
role
ecmo
sever
ard
open
best
potenti
candid
ecmo
patient
sever
ard
within
first
week
mechan
ventil
without
multipl
organ
optim
risktobenefit
ratio
ecmo
provid
centr
experienc
care
sever
ard
use
extracorpor
extracorpor
remov
partial
remov
venou
blood
use
moder
l
per
min
extracorpor
blood
flow
method
permit
use
low
tidal
volum
ml
per
kg
pbw
without
caus
sever
respiratori
socal
ultraprotect
strategi
shown
attenu
biomark
inflamm
bronchoalveolar
lavag
blood
pilot
trial
indic
patient
experi
ongo
vali
convent
protect
ventil
extracorpor
method
extracorpor
remov
carri
risk
especi
bleed
pend
result
ongo
studi
benefit
ultraprotect
ventil
associ
extracorpor
remov
outcom
patient
ard
remain
unknown
methylprednisolon
among
first
therapi
test
trial
prevent
acut
lung
intuit
appeal
antiinflammatori
properti
onefifth
patient
ard
receiv
system
although
efficaci
attenu
lung
injuri
remain
unclear
although
report
posit
effect
steroid
multicentr
trial
methylprednisolon
versu
placebo
persist
moder
sever
ard
observ
surviv
benefit
day
durat
steroid
acceler
resolut
respiratori
failur
circulatori
shock
also
increas
risk
neuromuscular
weak
patient
initi
steroid
day
ard
onset
experienc
increas
mortal
thu
steroid
probabl
initi
week
ard
onset
uncertain
risktobenefit
ratio
even
initi
earlier
unless
specif
caus
ard
pneumocysti
carinii
effect
steroid
adjunct
therapi
p
carinii
pneumonia
may
relat
antiinflammatori
effect
although
benefit
demonstr
convincingli
pathogen
caus
ard
balanc
role
corticosteroid
earli
ard
remain
controversi
owe
mix
result
exist
literatur
definit
largescal
trial
era
lungprotect
ventil
inhal
nitric
oxid
prostaglandin
achiev
select
vasodil
pulmonari
circul
improv
ventilationperfus
match
transient
oxygen
patient
howev
benefit
patientcentr
outcom
mortal
pulmonari
vasodil
could
benefit
patient
ard
associ
acut
cor
pulmonal
right
heart
failur
contribut
circulatori
highfrequ
oscillatori
ventil
hfov
mode
ventil
support
use
rapid
respiratori
rate
low
tidal
volum
attempt
maxim
lung
recruit
avoid
cyclic
alveolar
collaps
two
recent
trial
adult
hfov
confer
benefit
compar
convent
ventil
one
trial
mortal
increas
thu
hfov
use
extrem
caution
adult
ard
hfov
commonli
use
children
prospect
studi
current
evalu
effect
use
factori
design
ventil
mode
combin
control
breath
unassist
spontan
breath
airway
pressur
releas
ventil
may
improv
oxygen
haemodynam
decreas
need
howev
concern
vali
risk
warrant
limit
use
studi
multipl
pharmacolog
therapi
improv
clinic
outcom
ard
studi
phase
ii
phase
iii
trial
none
shown
efficaci
list
unsuccess
therapi
includ
surfact
replac
aerosol
intraven
agonist
prostaglandin
activ
protein
c
antioxid
supplement
ketoconazol
antifung
lisofyllin
antiinflammatori
recombin
human
factor
viia
colonystimul
factor
howev
certainli
possibl
one
treatment
might
effect
predict
enrich
strategi
incorpor
trial
design
illustr
recent
addit
optim
target
arteri
oxygen
arteri
concentr
defin
ard
critic
care
condit
target
establish
may
possibl
test
specif
oxygen
target
clinic
trial
longitudin
evalu
survivor
ard
help
spark
research
agenda
track
longterm
morbid
critic
ill
differ
assess
qol
function
use
ard
survivor
longterm
outcom
ard
focus
primarili
pulmonari
past
two
decad
assess
longerterm
outcom
expand
includ
sever
new
method
clinic
assess
method
includ
qol
measur
focus
limit
function
domain
includ
muscl
weak
quantit
walk
distanc
well
neurocognit
measur
includ
attent
memori
concentr
mood
disord
addit
data
collect
caregiv
burden
medic
complex
increas
healthcar
cost
consid
evolut
outcom
measur
survivor
ard
earli
report
observ
survivor
ard
experienc
obstruct
restrict
ventilatori
deficit
persist
week
month
recoveri
acut
variabl
outcom
among
survivor
may
relat
differ
studi
sampl
select
clinic
manag
acut
ill
durat
complet
followup
heterogen
baselin
pulmonari
diseas
variabl
contribut
longterm
respiratori
muscl
diaphragmat
muscl
weak
nevertheless
patient
recov
nearnorm
pulmonari
function
within
month
qol
studi
consist
demonstr
decrement
physic
function
domain
among
survivor
ard
earli
report
postul
decrement
might
due
exercis
limit
residu
pulmonari
function
later
studi
combin
pulmonari
function
outcom
measur
qol
assess
observ
pulmonari
function
selfperceiv
overal
health
gradual
improv
month
acut
ill
howev
sever
disabl
wholli
explain
chang
pulmonari
function
respiratori
aetiolog
report
dysfunct
uncertain
later
studi
combin
measur
pulmonari
function
evalu
qualityadjust
life
year
use
qualiti
wellb
scale
gener
health
questionnair
measur
wellb
previou
day
term
physic
activ
social
activ
mobil
symptom
found
ard
survivor
poor
qualityadjust
surviv
associ
import
ill
burden
specif
contributor
dysfunct
remain
subsequ
studi
combin
serial
qol
pulmonari
function
walk
test
commonli
use
test
assess
cardiopulmonari
capac
data
inperson
histori
physic
examin
evalu
pattern
cost
healthcar
detail
followup
evalu
investig
observ
survivor
ard
signific
exercis
limit
poor
physic
qol
followup
relat
mark
muscl
wast
weak
myriad
physic
disabl
includ
heterotop
ossif
joint
contractur
tracheal
stenosi
cosmet
concern
relat
scar
tracheostomi
central
line
chest
tube
site
studi
focus
attent
muscl
dysfunct
major
morbid
ard
serv
highlight
preval
persist
medic
complex
critic
group
investig
continu
followup
year
ard
note
persist
disabl
compromis
qol
associ
increas
cost
healthcar
find
robust
replic
mani
hopkin
group
first
describ
neurocognit
mood
disord
outcom
survivor
ard
note
import
decrement
attent
concentr
process
speed
memori
execut
function
persist
year
discharg
intens
posttraumat
stress
disord
patient
ard
also
describ
associ
decrement
mental
health
domain
short
form
survey
qol
observ
led
way
investig
evalu
neurocognit
dysfunct
risk
factor
ard
survivor
critic
ill
includ
hypoglycaemia
intens
care
hypoxaemia
fluid
durat
premorbid
function
observ
persist
muscl
wast
weak
ard
survivor
spawn
intens
interest
entiti
describ
intens
care
unitacquir
weak
icuaw
consequ
myosin
deplet
myopathi
axonopathi
occur
isol
injuri
diaphragm
muscl
axial
skeleton
due
least
part
upregul
ubiquitinproteasom
pathway
mark
proteolysi
begin
within
hour
critic
may
continu
throughout
first
week
recent
semin
observ
show
muscl
repair
episod
critic
ill
may
differenti
recoveri
contractil
forc
muscl
mass
may
discord
longterm
one
challeng
studi
longterm
outcom
know
baselin
statu
patient
ard
thu
extent
deficit
manifest
develop
ard
alway
clear
addit
deficit
may
function
prolong
sever
critic
ill
rather
specif
ard
past
two
decad
outcom
ard
improv
consider
first
report
syndrom
major
patient
surviv
howev
mortal
remain
seriou
threat
longterm
complic
remain
common
problemat
survivor
addit
research
sever
front
may
help
improv
prognosi
mechanist
perspect
need
strategi
mitig
lung
endotheli
epitheli
injuri
novel
approach
promot
lung
endotheli
epitheli
repair
addit
need
optim
preclin
model
test
novel
therapi
ard
improv
pipelin
drug
discoveri
improv
patient
outcom
clinic
set
increas
recognit
ard
region
world
import
better
identifi
patient
earlier
clinic
cours
support
care
lungprotect
ventil
conserv
fluid
approach
implement
prognost
andor
predict
enrich
approach
includ
biolog
clinic
variabl
random
trial
may
improv
chanc
identifi
respons
subset
patient
ard
question
whether
syndrom
definit
ard
continu
use
given
lack
specif
overlap
distinct
syndrom
ard
mimic
relentless
failur
pharmacotherapeut
condit
howev
yet
consensu
within
field
suitabl
altern
approach
new
evid
degre
pulmonari
oedema
quantifi
chest
method
appli
rapidli
assess
four
quadrant
standard
radiograph
intens
care
unit
addit
clinic
practic
method
ventilatori
ratio
estim
pulmonari
dead
space
thu
modifi
lung
injuri
score
incorpor
oxygen
abnorm
level
peep
pulmonari
dead
space
degre
pulmonari
oedema
may
prove
use
combin
promis
biolog
variabl
risk
stratif
clinic
trial
novel
diagnost
approach
may
improv
abil
identifi
treat
caus
pathogen
patient
ard
therebi
improv
patient
extracorpor
therapi
may
provid
lifesustain
support
sever
multipathway
target
cellbas
therapi
mesenchym
stromal
cell
show
promis
potenti
therapeut
option
capac
reduc
lung
vascular
injuri
restor
alveolar
epitheli
fluid
transport
properti
remov
alveolar
oedemat
fluid
switch
proinflammatori
respons
proresolv
final
increas
understand
import
longterm
patientcentr
outcom
may
lead
improv
mechanist
understand
caus
sequela
improv
effort
design
trial
target
